A Phase 4 interventional study of Tranexamic Acid (TXA) in Trauma Coagulopathy and Hemorrhage, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies testing Tranexamic Acid in Hemorrhage — 21 open to participants now, 24 under way, 11 of them phase 3. Tranexamic Acid · Hemorrhage.
Among the 133 studies testing Tranexamic Acid in Hemorrhage, this one is the 98th largest by planned enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2026, is one of 51 in phase 4, reaches primary completion later than 13 of the 23 other live ones, and was the 133rd registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →21 of the 133 studies testing Tranexamic Acid in Hemorrhage are open now, in 12 countries. Recruiting first, the newest first:
London School of Hygiene and Tropical Medicine · Sites in Nigeria, Pakistan, Tanzania
Ages 18+ · Women only
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Sites in North Macedonia
Ages 65+
King Abdullah International Medical Research Center · Sites in Saudi Arabia
Ages 18–70
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
University of California, San Diego · Sites in United States
Ages 18+ · Women only · Healthy volunteers
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 40 · Phase 4 51
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 102 across the 132 interventional studies. Of the 82 that completed or were terminated, 23 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 133 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
8 of the studies testing Tranexamic Acid in Hemorrhage that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229483Phase 3Stephen LownieThe Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies | 2027-01-31 |
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT07869537Second Affiliated Hospital, Zhejiang University, School of MedicineThe Safety of Simplified Tranexamic Acid Regimen | 2027-03-31 |
| NCT06820177University of California, San DiegoTranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 133 studies testing Tranexamic Acid in Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Trauma causes at least 5.8 million deaths worldwide annually, accounting for 1 in 10 of all global deaths. Uncontrolled bleeding within 24 hours after trauma is the leading cause of death in trauma patients, and about one-third of patients present with trauma-induced coagulopathy on admission. Fatal severe traumatic hemorrhage is the most common preventable factor contributing to death.
Tranexamic acid (TXA), a synthetic lysine derivative, competitively inhibits plasminogen activation, preventing fibrin clot breakdown and thereby enhancing hemostasis and reducing blood loss. Randomized controlled trials such as CRASH-2 have confirmed that TXA significantly reduces mortality in patients with severe traumatic bleeding. TXA has therefore become a cornerstone of traumatic hemorrhage treatment, with current international guidelines recommending 1 g intravenous bolus (over >10 minutes) plus 1 g intravenous maintenance infusion (over 8 hours).
However, severe traumatic hemorrhage is typically managed in high-pressure, chaotic battlefield or emergency settings, where this complex, time-sensitive, multi-step divided regimen is difficult to fully execute in real-world practice. The omission rate of the second maintenance infusion is particularly high, reaching up to 67% during prehospital-to-hospital handover. Rowell et al. showed that even with a strict research protocol, completion of the planned 8-hour in-hospital maintenance infusion was only about 70%. Previous pharmacokinetic studies found that without the second maintenance dose, 21% of patients receiving an initial 1 g dose had already failed to achieve effective plasma concentrations at hospital admission (approximately 1.5 hours post-dose). Thus, the inherent difficulty of fully executing the divided regimen may prevent patients from receiving the full benefits of TXA.
To address this, a simplified regimen of a single 2 g loading dose without maintenance infusion has been recommended in recent expert consensus statements, especially for prehospital or battlefield settings. However, these recommendations were mainly based on the 2020 Rowell et al. randomized controlled study, whose exploratory analysis suggested potential mortality reduction with the simplified regimen. That study enrolled patients with traumatic brain injury and had limited statistical power, so evidence on the efficacy and safety of the simplified regimen in patients with severe traumatic hemorrhage remains lacking. Based on the pharmacokinetic study by Grassin-Delyle et al., a single 2 g loading dose is hypothesized to maintain effective concentrations during the peak fibrinolytic period (within 3 hours post-injury), while the transient peak plasma concentration remains well below the toxicity threshold of 500 μg/mL. We therefore hypothesize that, in patients with severe traumatic hemorrhage, the simplified TXA regimen is non-inferior to the divided regimen in efficacy, including bleeding control.
However, the primary limitation of a large randomized controlled trial to verify this hypothesis is that safety concerns regarding the simplified regimen due to higher transient plasma concentrations compared with the divided regimen have not been clearly resolved. Previous systematic reviews concluded that safety events such as thrombosis and seizures are dose-dependent, and that a total daily dose not exceeding 2 g is safe. Previous pharmacokinetic studies also suggest that the transient peak concentration of the simplified regimen should be well below the toxicity threshold. Although expert consensus has recommended the simplified regimen, suggesting it can be considered safe, studies directly comparing the two regimens are lacking, particularly regarding whether the simplified regimen increases safety risks when the total dose is identical. Before conducting a larger, more definitive efficacy trial, it is also important to evaluate recruitment rates, protocol adherence, accurate sample size estimation, and other potential barriers. For these reasons, we designed this pilot study, primarily to evaluate the safety of the simplified TXA regimen compared with the divided regimen in patients with traumatic hemorrhagic shock, and the feasibility of a subsequent randomized controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tranexamic Acid was administered intravenously within 3 hours after injury, with a loading dose of 2 g, and the infusion was completed after more than 20 minutes without a second dose.
Drug: Tranexamic Acid (TXA)
Tranexamic Acid is administered intravenously within 3 hours after injury, with a loading dose of 1 g, and the infusion is completed after more than 10 minutes. The second dose of 1 g is maintained for 8 hours.
Drug: Tranexamic Acid (TXA)
Tranexamic Acid
The incidence of thrombotic events
Including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, cerebral infarction and other thrombotic events
Time frame: in hospital
the incidence of deep venous thrombosis
Time frame: 24 hour
the incidence of deep venous thrombosis
Time frame: in hospital
the incidence of pulmonary embolism
Time frame: in hospital
the incidence of myocardial infarction
Time frame: in hospital
the incidence of cerebrovascular embolism
Time frame: in hospital
the incidence of other thrombotic events
Time frame: in hospital
the incidence of seizure or seizure-like activity
Time frame: in hospital
The incidence of hypotension
Time frame: Within 30min after TXA bolus
The duration of hypotension after TXA bolus
Time frame: in hospital
The incidence of acute kidney injury
Time frame: in hospital
Percentage of clot lysed at 30 min following maximum amplitude
CL30 \< 0.8% (fibrinolysis shutdown), 0.8≤CL30≤3% (normal ), and CL30 \> 3% (hyperfibrinolysis)
Time frame: 3 hour after TXA bolus
Percentage of clot lysed at 30 min following maximum amplitude
CL30 \< 0.8% (fibrinolysis shutdown), 0.8≤CL30≤3% (normal ), and CL30 \> 3% (hyperfibrinolysis)
Time frame: 24 hour
mortality
Time frame: 24 hour
mortality of bleeding
Time frame: 24 hour
mortality
Time frame: Day 28
mortality of bleeding
Time frame: Day 28
Total blood product consumption
Time frame: 24 hour
Red blood cell consumption
Time frame: 24 hour
Fresh frozen plasma consumption
Time frame: 24 hour
Platelet concentrate consumption
Time frame: 24 hour
Hospital-free days
Time frame: Day 28
Ventilator-free days
Time frame: Day 28
ICU-free days
Time frame: Day 28
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 92 non-industry phase 4 interventional studies under Hemorrhage, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 5 months is below that.
Counting every sponsor, half of 96 studies reached it within 28 months; a quarter within 18 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Second Affiliated Hospital, Zhejiang University, School of Medicine →